Business, energy, technology, markets and global industry news from Business News Today

Oruka Therapeutics

PharmaDeviceNews Oruka Therapeutics
Representative image of plaque psoriasis treatment as Oruka Therapeutics’ ORKA-001 achieves 61% complete skin clearance in a positive Phase 2b EVERLAST-B clinical trial.
Pharma & Biotech

ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027

Oruka Therapeutics' ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis testing. Explore the results and Phase 3 plans.

Read More
Representative image: Oruka Therapeutics reports ORKA-001 psoriasis responses deepening through Week 28, with 71.4% of patients achieving complete skin clearance without additional dosing after Week 4.
Features & Analysis

Long-acting ORKA-001 maintains deep psoriasis responses as Phase 3 planning approaches

ORKA-001 reaches 71.4% complete psoriasis clearance at Week 28 without redosing. See what the data mean for Oruka’s long-acting biologic strategy.

Read More